Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
16.30
+0.37 (2.32%)
At close: Apr 14, 2026, 4:00 PM EDT
16.31
+0.01 (0.06%)
Pre-market: Apr 15, 2026, 7:27 AM EDT
Olema Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Olema Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $44.89, which forecasts a 175.40% increase in the stock price over the next year. The lowest target is $27 and the highest is $62.
Price Target: $44.89 (+175.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Olema Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Mar 27, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $43 → $40 | Strong Buy | Initiates | $43 → $40 | +145.40% | Mar 19, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $55 → $58 | Buy | Maintains | $55 → $58 | +255.83% | Mar 18, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $38 → $27 | Strong Buy | Maintains | $38 → $27 | +65.64% | Mar 18, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $60 → $62 | Strong Buy | Maintains | $60 → $62 | +280.37% | Mar 17, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
25.91M
EPS This Year
-2.30
from -1.87
EPS Next Year
-2.55
from -2.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 52.5M | |||
| Avg | n/a | 25.9M | |||
| Low | n/a | 2.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.00 | -1.84 | |||
| Avg | -2.30 | -2.55 | |||
| Low | -2.70 | -3.51 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.